Clinical trials: completed, sponsored by Deciphera Pharmaceuticals, LLC
- Lead sponsor (exact) Deciphera Pharmaceuticals, LLC
- Status Completed
- Funder type Industry (pharma, biotech, devices)
Healthy Participants
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants.
- Trial name
- NCT07539090
- Testing
- Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Participants
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants.
- Trial name
- NCT07158411
- Testing
- Vimseltinib, Metformin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Participants
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male…
- Trial name
- NCT07158398
- Testing
- Vimseltinib, Rosuvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
GIST - Gastrointestinal Stromal Tumor
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
- Trial name
- NCT04530981
- Testing
- Ripretinib, Repaglinide
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies.
- Trial name
- INVICTUS (NCT03353753)
- Testing
- DCC-2618
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 129 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Chronic Myeloid Leukemia
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Rationale: DCC-2036 is a potent broad spectrum inhibitor of BCR-ABL kinase. Inhibition of BCR-ABL has been validated for effective treatment of chronic myeloid leukemia (CML).
- Trial name
- NCT00827138
- Testing
- DCC-2036
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Deciphera Pharmaceuticals, LLC